Theravance Inc and GlaxoSmithKline Plc announces positive results from studies comparing ANORO ELLIPTA With SERETIDE DISKUS and ADVAIR DISKUS in Patients With COPD

Friday, 14 Mar 2014 08:00am EDT 

Theravance Inc and GlaxoSmithKline plc:Positive results from three phase III studies.Two studies comparing efficacy and safety of combination anticholinergic / long-acting beta2-adrenergic agonist, Anoro Ellipta with inhaled corticosteroid / long-acting beta2-adrenergic agonist combination, Advair Diskus and third comparing efficacy.Safety of Anoro Ellipta with Seretide Diskus 'FSC 500/50' in patients with chronic obstructive pulmonary disease (COPD) and no history of moderate to severe COPD exacerbations in the last year.In each of studies UMEC/VI achieved statistically improvement in lung function, measured as weighted mean forced expiratory volume in one second (wm FEV1) over 0-24 hours at the end of 12 week study (day 84), compared to either dose of FSC. 

Company Quote

0.43 +0.95%
24 Oct 2014